Welcome to our dedicated page for Ingevity SEC filings (Ticker: NGVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ingevity Corporation filings document formal disclosure for its specialty materials business, public-company governance, and capital structure. Form 8-K reports cover operating results, segment reporting presentation, credit agreement amendments, material agreements, and completed dispositions of North Charleston crude tall oil refinery assets and the majority of the Industrial Specialties product line.
Proxy and annual-meeting filings disclose director elections, board structure, executive compensation matters, shareholder voting results, and amendments to the company’s equity incentive plan. The filing record also includes disclosures tied to financing arrangements, continuing-operations measures, and governance matters affecting Ingevity’s common stock as a NYSE-listed issuer.
NARWOLD KAREN G reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp director receives equity award through a grant of 1,904 shares of common stock to Karen G. Narwold. The grant is reported at a price of $0.00 per share as a compensation-related award, not an open-market purchase, and increases her direct holdings to 18,900 shares.
The award represents restricted stock units granted under Ingevity Corporation's 2025 Omnibus Incentive Plan and is scheduled to vest in full on April 30, 2027. This filing records a routine equity-based compensation grant rather than a discretionary stock trade.
Segal Francis David reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp director Francis David Segal reported receiving an equity award under the company’s 2025 Omnibus Incentive Plan. He was granted 1,904 shares of Common Stock at no cost, structured as restricted stock units that will vest in full on April 30, 2027. Following this grant, he directly holds 8,284 shares of Ingevity common stock.
Ingevity Corp director Kevin J. Willis received an equity award of 1,904 deferred stock units. The grant reflects his election to take deferred stock units instead of the usual annual restricted stock unit grant for non-employee directors.
The deferred stock units will vest on April 30, 2027 and will convert into an equal number of Ingevity common shares when his board service ends, under the company’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. After this award, he holds 11,081 shares directly.
Ingevity director Benjamin G. Wright received an equity grant in the form of deferred stock units. He was granted 1,904 deferred stock units in lieu of the annual non-employee director restricted stock unit grant, at no cash cost per unit. These units will vest on April 30, 2027 and will convert into the same number of Ingevity common shares after his board service ends, under the company’s Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. Following this grant, he directly holds 11,948 shares.
Ingevity Corp reported that Vanguard Capital Management holds 1,853,415 shares of Common Stock, representing 5.26% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 1,853,415 shares and sole voting power over 271,544 shares. The submission describes ownership held by Vanguard Capital Management LLC and affiliates, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd., and was signed by Ashley Grim on 04/30/2026.
Ingevity Corp ownership filing shows 2,209,879 shares beneficially owned by Vanguard Portfolio Management, representing 6.27% of common stock. The filing reports sole voting power of 33,148 shares and sole dispositive power over 2,209,879 shares. The filing states these holdings include securities held for Vanguard funds and client accounts managed by affiliates, per SEC Release No. 34-39538.
Ingevity Corporation completed the sale of its Ozark Materials road markings business to PPG Industries in an all-cash transaction delivering approximately $65 million in proceeds to Ingevity, subject to customary adjustments.
The divestiture is limited to the Ozark Materials road markings business and does not affect Ingevity’s Pavement Technologies operations, where the company says it remains fully committed to serving paving customers. Ingevity states that the sale advances its strategy to focus on businesses aligned with its core capabilities. The company plans to update its full-year 2026 guidance for the impact of this transaction when it releases first quarter 2026 financial results, while affirming prior guidance excluding that impact.
Ingevity Corp President & CEO David H. Li reported routine tax-related share dispositions rather than open-market sales. On April 7, 2026, a total of 16,676 shares of Common Stock were withheld at $70.57 per share to cover tax obligations. After these transactions, Li directly held 140,636 shares of Ingevity common stock. A footnote notes that this total includes 422 ESPP shares purchased for the January 1 to March 31, 2026 period at 85% of the December 31, 2025 closing price.
Ingevity Corp director Francis David Segal received a grant of 329 vested deferred stock units at $72.28 per unit. These units were issued in lieu of quarterly director fees and increase his directly owned common stock-related position to 6,380 shares.
The deferred stock units will convert into an equal number of Ingevity common shares when his board service ends, under the company’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.
Ingevity Corp director J. Kevin Willis reported an equity award of 398 shares of Common Stock on Form 4. The award reflects vested deferred stock units elected in lieu of quarterly director fees at an implied price of $72.28 per share. Following this grant, Willis directly holds 9,177 shares. These deferred stock units will convert into an equal number of Ingevity common shares when his board service ends under the company’s Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.